2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Omics Technologies, Computational Biology, Emerging Technologies, Gene Editing, Profiling, Treatment Considerations, Biological Therapies, Checkpoint Inhibitor, Women’s Health, Artificial Intelligence (AI), Machine Learning, Biological Processes, Pathogenesis, Immune Mechanism, Metabolism, Molecular Biology, Diseases, Bleeding and Clotting, Platelet Disorders, Thromboembolism, Thrombotic Disorders, Immunology, Research, Fundamental Science, Translational Research, Study Population, Human, Adult, Animal Model
PAPER

4826 Platelet activation and mitochondrial dysfunction may contribute to the mechanisms of severe thrombocytopenia in TTP

Huan Dong, MD, PhD, X. Long Zheng, MD, PhD2
1 The University of Kansas Medical Center, Kansas City, Kansas, United States
2 The University of Kansas Medical Center, Kansas City, Kansas, United States

Background. Thrombotic thrombocytopenic purpura (TTP), resulting from severe deficiency of plasma ADAMTS13 activity, is characterized by severe thrombocytopenia and microangiopathic hemolytic anemia. While consumption in microvascular thrombosis is thought to be the cause of severe thrombocytopenia in TTP, the exact mechanism remains poorly understood.

Aims: This study aims to determine if ADAMTS13 deficiency results in megakaryocyte/platelet metabolic reprogramming and activation, leading to the perturbation of megakaryopoiesis and platelet destruction.

Methods: Light transmission aggregometry determined the agonist-induced platelet aggregation. Flow cytometry assessed the platelet activation, phosphatidylserine (PS) exposure and platelet lifespan. Seahorse extracellular flux analysis together with additional flow cytometry determined the platelet mitochondrial oxygen consumption rate (OCR), extracellular acidification rate (ECAR), reactive oxygen species (ROS), and mitochondrial mass, as well as mitochondrial membrane potential (TMRE). Platelet count, MPV, reticulated platelets, platelet lifespan, and bone marrow megakaryocyte number, ploidy, and mitochondrial characteristics were also analyzed. Therapeutic rescue for functional restoration was evaluated by plasma (ADAMTS13) infusion or AAV-mediated expression of MDTCS fragment.

Results: Rats with severe ADAMTS13 deficiency developed spontaneous TTP, presented with severe thrombocytopenia with an increased mean platelet volume (MPV) and reticulated platelet counts, consistent with enhanced megakaryopoiesis. Indeed, bone marrow megakaryocytes in TTP rats were significantly increased in numbers and polyploidization, but altered mitochondrial characteristics, consistent with an altered megakaryopoiesis. Platelets from TTP rats exhibited an increased expression of CD62P and PS exposure, but impaired collagen- and thrombin-induced aggregation in vitro, suggesting platelet dysfunction. Metabolic profiling revealed impaired mitochondrial bioenergetics, with significantly reduced OCR (oxidative phosphorylation) and EACR (glycolysis). These platelets also exhibited reduced mitochondrial ROS, mitochondrial mass, mitochondrial membrane potential, and intracellular calcium mobilization, consistent with the Seahorse results. Importantly, a restoration of ADAMTS13 activity by either plasma infusion or AAV-mediated expression of MDTCS fragment significantly increased platelet counts and reduced platelet activation, PS exposure, and mitochondrial dysfunction, suggesting that these abnormalities are reversible following ADAMTS13 replacement.

Conclusions: Our results demonstrate that ADAMTS13 deficiency may directly cause megakaryocyte/platelet metabolic reprogramming and activation, which results in disrupted megakaryopoiesis and platelet homeostasis, leading to thrombocytopenia in TTP. Restoration of ADAMTS13 rapidly reverses platelet activation but does not fully restore platelet mitochondrial function. Our findings reveal potential novel mechanism of severe thrombocytopenia, highlighting the critical role of VWF-mediated platelet signaling in platelet activation and mitochondrial dysfunction in pathogenesis of TTP.

Abbreviations: TTP, thrombotic thrombocytopenic purpura; PS, phosphatidylserine; ECAR, extracellular acidification rate; OCR, oxygen consumption rate; ROS, reactive oxygen species; MPV, mean platelet volume; MDTCS, an ADAMTS13 variant truncated after the spacer domain. 

Huan Dong, MD, PhD: No relevant conflicts of interest to declare.